NCT01454115View on ClinicalTrials.gov

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Alzheimer's Disease
Interventions
DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 0.3 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 1.5 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 5.0 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 15.0 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 50 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 100 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 200 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 400 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Capsule, Oral, 50 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 800 mg, Once daily, once

DRUG

Placebo matching BMS-708163

Oral Solution, Oral, 0 mg, Once daily, once

DRUG

Placebo matching BMS-708163

Capsule, Oral, 0 mg, Once daily, once

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY